1. Home
  2. Live Updates
  3. Vineet gala

Live Breaking News & Updates on Vineet gala

Stay informed with the latest breaking news from Vineet gala on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Vineet gala and stay connected to the pulse of your community

Wockhardt's R&D prowess attracts marquee investors Madhusudan Kela, Prashant Jain

Wockhardt has two molecules — Nafithromycin (WCK 4873) for treating pneumonia and WCK 5222 for urinary tract infection, in development phases, with launched lined up for FY25 and FY26

India , Prashant-jain , Madhusudan-kela , Pfizer , Prudential , Tata-indian-opportunities-fund , Mirae-asset , Habilf-khorakiwala , Vineet-gala , Xylem-investment , Wockhardt , Ip

Why is Indian pharma failing to meet US standards?

It’s not as if domestic manufacturing has suddenly become sloppy. A closer look will reveal the strides made by Indian pharma firms as they attempt to break into the complex drugs space, which attracts higher scrutiny.

Sun-pharma-mohali , Drug-administration , Cipla , Vineet-gala , Xylem-investment-managers , Sun-pharma , Usfda , Pca-laboratories , Ipla , Un-pharmaceutical-industries , Rugmakers , S-generics

Lupin shares bounce back 10.5% in one month; should investors jump on the bandwagon?

Opinion is split, but most analysts recommend waiting for more clarity from Lupin.

Nagpur , Maharashtra , India , Drug-administration , Nifty-pharma , Vineet-gala , Xylem-investment-managers , Lupin , Harma , Harmaceuticals , Harma-sector